DK2605794T3 - Oligonukleotidchelatkomplekser - Google Patents
Oligonukleotidchelatkomplekser Download PDFInfo
- Publication number
- DK2605794T3 DK2605794T3 DK11817618.9T DK11817618T DK2605794T3 DK 2605794 T3 DK2605794 T3 DK 2605794T3 DK 11817618 T DK11817618 T DK 11817618T DK 2605794 T3 DK2605794 T3 DK 2605794T3
- Authority
- DK
- Denmark
- Prior art keywords
- rep
- ons
- oligonucleotide
- chelate
- calcium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
Claims (9)
1. Farmaceutisk sammensætning til anvendelse til undertrykkelse eller reducering af subkutane injektionssted-reaktioner hos et individ af et subkutant administreret oligonukleotid, hvilken farmaceutiske sammensætning omfatter: • et oligonukleotidchelatkompleks omfattende to eller flere oligonukleotider bundet ved deres phosphodiester-backbones af en multivalent kation; og • en farmaceutisk acceptabel excipiens, hvor mindst et oligonukleotid af komplekset har mindst én phosphorthioatbinding og hvor den multivalente kation er en divalent metalkation.
2. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor bindingen mellem to eller flere oligonukleotider sker ved det ikke-brodannende oxygen (eller svovl i tilfældet af phosphorthioering)-atomer i phosphordiesterbindingen, og hvor olinukleotidet er valgt fra følgende tabel:
3. Farmaceutisk sammensætning til anvendelse ifølge kravene 1 eller 2, hvor den divalente metalkation er calcium.
4. Farmaceutisk sammensætning til anvendelse ifølge kravene 1 eller 2, hvor den divalente metalkation er magnesium.
5. Farmaceutisk sammensætning til anvendelse ifølge kravene 1 eller 2, hvor den divalente metalkation er kobolt, jern (2+), mangan, kobber eller zink.
6. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 og 3 til 5, hvor chelatkomplekset omfatter mindst ét dobbeltstrenget oligonukleotid.
7. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor chelatkomplekset omfatter mindst ét fuldt phosphorthioeret oligonukleotid.
8. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor chelatkomplekset omfatter mindst ét oligonukleotid med en 2'-modificeret ribose.
9. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 8, hvor chelatkomplekset omfatter oligonukleotid valgt fra gruppen bestående af SEQ ID NO: 3 til 14.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37525710P | 2010-08-20 | 2010-08-20 | |
| PCT/CA2011/000956 WO2012021985A1 (en) | 2010-08-20 | 2011-08-18 | Oligonucleotide chelate complexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2605794T3 true DK2605794T3 (da) | 2016-10-24 |
Family
ID=45594559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11817618.9T DK2605794T3 (da) | 2010-08-20 | 2011-08-18 | Oligonukleotidchelatkomplekser |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US8513211B2 (da) |
| EP (1) | EP2605794B1 (da) |
| JP (1) | JP5775581B2 (da) |
| KR (3) | KR101606495B1 (da) |
| CN (2) | CN103052405B (da) |
| AU (1) | AU2011291401B2 (da) |
| BR (1) | BR112013003875B1 (da) |
| CA (2) | CA2855690C (da) |
| CL (1) | CL2013000445A1 (da) |
| CO (1) | CO6670525A2 (da) |
| CR (1) | CR20130069A (da) |
| CU (1) | CU20130022A7 (da) |
| CY (1) | CY1118207T1 (da) |
| DK (1) | DK2605794T3 (da) |
| DO (1) | DOP2013000041A (da) |
| EA (1) | EA026660B1 (da) |
| EC (1) | ECSP13012449A (da) |
| ES (1) | ES2598556T3 (da) |
| GT (1) | GT201300040A (da) |
| HK (2) | HK1184058A1 (da) |
| HR (1) | HRP20161333T1 (da) |
| HU (1) | HUE029521T2 (da) |
| IL (1) | IL224237A (da) |
| LT (1) | LT2605794T (da) |
| MX (1) | MX340294B (da) |
| MY (1) | MY160961A (da) |
| NZ (1) | NZ606364A (da) |
| PL (1) | PL2605794T3 (da) |
| PT (1) | PT2605794T (da) |
| RS (1) | RS55245B1 (da) |
| SG (1) | SG187165A1 (da) |
| SI (1) | SI2605794T1 (da) |
| SM (1) | SMT201600370B (da) |
| WO (1) | WO2012021985A1 (da) |
| ZA (1) | ZA201300497B (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2049664B1 (en) | 2006-08-11 | 2011-09-14 | Prosensa Technologies B.V. | Single stranded oligonucleotides complementary to repetitive elements for treating DNA repeat instability associated genetic disorders |
| CA2723672C (en) | 2007-05-11 | 2019-09-03 | Adynxx, Inc. | Gene expression and pain |
| ES2914775T3 (es) | 2007-10-26 | 2022-06-16 | Academisch Ziekenhuis Leiden | Medios y métodos para contrarresta trastornos del músculo |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| CA2862628C (en) | 2012-01-27 | 2021-08-24 | Prosensa Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
| CA3103101C (en) | 2012-04-23 | 2023-01-17 | Biomarin Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders |
| CA2872901A1 (en) | 2012-05-10 | 2013-11-14 | Adynxx, Inc. | Formulations for the delivery of active ingredients |
| EA035967B1 (ru) * | 2012-05-18 | 2020-09-07 | Репликор Инк. | Композиции для лечения гепатита в, содержащие олигонуклеотидные хелатные комплексы |
| AR091065A1 (es) * | 2012-05-18 | 2014-12-30 | Replicor Inc | Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral |
| AU2013285698A1 (en) | 2012-07-03 | 2015-02-19 | Biomarin Technologies B.V. | Oligonucleotide for the treatment of muscular dystrophy patients |
| BR112015003985A2 (pt) * | 2012-08-30 | 2017-08-08 | Replicor Inc | métodos para tratamento de infecções de hepatite b e hepatite d |
| CN113750112A (zh) | 2014-07-10 | 2021-12-07 | 里普利科股份有限公司 | 治疗b型肝炎和d型肝炎病毒感染的方法 |
| PT3180434T (pt) | 2014-08-15 | 2019-10-29 | Adynxx Inc | Chamarizes oligonucleotídicos para o tratamento da dor |
| WO2016030863A1 (en) | 2014-08-29 | 2016-03-03 | Glaxosmithkline Intellectual Property Development Limited | Compounds and methods for treating viral infections |
| AU2016250576C1 (en) * | 2015-04-23 | 2021-05-06 | Geron Corporation | Methods of polynucleotide preparation using multivalent cation salt compositions |
| US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| CA3117163A1 (en) * | 2018-11-08 | 2020-05-14 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| WO2021198958A1 (en) | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Nucleic acid polymers |
| US20220160748A1 (en) * | 2020-11-20 | 2022-05-26 | Aligos Therapeutics, Inc. | Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting |
| TW202245809A (zh) | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | 用於治療b型肝炎病毒感染之組合療法 |
| WO2022152869A1 (en) | 2021-01-15 | 2022-07-21 | Janssen Sciences Ireland Unlimited Company | Use of oligonucleotides for individuals with hepatic impairment |
| CA3224600A1 (en) | 2021-07-09 | 2023-01-12 | Glaxosmithkline Intellectual Property (No.3) Limited | Use of oligonucleotides for individuals with renal impairment |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001514873A (ja) * | 1997-08-20 | 2001-09-18 | ソーマジェニックス インコーポレイテッド | 結合特性が改善されたアンチセンスおよびアンチジーン治療薬並びにそれらの使用方法 |
| JP3667047B2 (ja) * | 1997-09-12 | 2005-07-06 | キヤノン株式会社 | 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法 |
| US6653467B1 (en) * | 2000-04-26 | 2003-11-25 | Jcr Pharmaceutical Co., Ltd. | Medicament for treatment of Duchenne muscular dystrophy |
| JP4836366B2 (ja) * | 2000-08-25 | 2011-12-14 | 雅文 松尾 | デュシェンヌ型筋ジストロフィー治療剤 |
| US20070105116A1 (en) | 2003-09-02 | 2007-05-10 | Japan Science And Technology Agency | Metal complex type nucleic acid |
| WO2005026188A1 (ja) * | 2003-09-08 | 2005-03-24 | Japan Science And Technology Agency | 金属錯体型核酸 |
| CA2613101A1 (en) * | 2005-07-01 | 2007-01-11 | Bioveris Corporation | Compositions and methods for detecting, amplifying, and/or isolating nucleic acids |
| WO2009065181A1 (en) * | 2007-11-21 | 2009-05-28 | Apollo Life Sciences Limited | Nanostructures suitable for delivery of agents |
-
2011
- 2011-08-18 CN CN201180035946.6A patent/CN103052405B/zh active Active
- 2011-08-18 CN CN201410046103.1A patent/CN103768086B/zh active Active
- 2011-08-18 EP EP11817618.9A patent/EP2605794B1/en active Active
- 2011-08-18 PT PT118176189T patent/PT2605794T/pt unknown
- 2011-08-18 NZ NZ606364A patent/NZ606364A/en unknown
- 2011-08-18 WO PCT/CA2011/000956 patent/WO2012021985A1/en active Application Filing
- 2011-08-18 MY MYPI2013000544A patent/MY160961A/en unknown
- 2011-08-18 CA CA2855690A patent/CA2855690C/en active Active
- 2011-08-18 JP JP2013524318A patent/JP5775581B2/ja active Active
- 2011-08-18 BR BR112013003875-6A patent/BR112013003875B1/pt active IP Right Grant
- 2011-08-18 PL PL11817618T patent/PL2605794T3/pl unknown
- 2011-08-18 KR KR1020137007008A patent/KR101606495B1/ko active IP Right Grant
- 2011-08-18 KR KR20157007582A patent/KR20150039873A/ko not_active Application Discontinuation
- 2011-08-18 SI SI201130985A patent/SI2605794T1/sl unknown
- 2011-08-18 RS RS20160869A patent/RS55245B1/sr unknown
- 2011-08-18 AU AU2011291401A patent/AU2011291401B2/en active Active
- 2011-08-18 ES ES11817618.9T patent/ES2598556T3/es active Active
- 2011-08-18 LT LTEP11817618.9T patent/LT2605794T/lt unknown
- 2011-08-18 US US13/212,306 patent/US8513211B2/en active Active
- 2011-08-18 MX MX2013001668A patent/MX340294B/es active IP Right Grant
- 2011-08-18 CA CA2806616A patent/CA2806616C/en active Active
- 2011-08-18 DK DK11817618.9T patent/DK2605794T3/da active
- 2011-08-18 SG SG2013004957A patent/SG187165A1/en unknown
- 2011-08-18 HU HUE11817618A patent/HUE029521T2/en unknown
- 2011-08-18 EA EA201300259A patent/EA026660B1/ru unknown
- 2011-08-18 KR KR1020157017340A patent/KR20150082685A/ko not_active Application Discontinuation
-
2013
- 2013-01-15 IL IL224237A patent/IL224237A/en active IP Right Grant
- 2013-01-18 ZA ZA2013/00497A patent/ZA201300497B/en unknown
- 2013-02-11 CO CO13027675A patent/CO6670525A2/es unknown
- 2013-02-13 CL CL2013000445A patent/CL2013000445A1/es unknown
- 2013-02-14 GT GT201300040A patent/GT201300040A/es unknown
- 2013-02-14 DO DO2013000041A patent/DOP2013000041A/es unknown
- 2013-02-19 CR CR20130069A patent/CR20130069A/es unknown
- 2013-02-19 EC ECSP13012449 patent/ECSP13012449A/es unknown
- 2013-02-20 CU CU2013000022A patent/CU20130022A7/es unknown
- 2013-05-30 US US13/905,318 patent/US8716259B2/en active Active
- 2013-10-14 HK HK13111542.5A patent/HK1184058A1/zh unknown
- 2013-10-14 HK HK14111304.2A patent/HK1198123A1/xx unknown
-
2016
- 2016-10-12 HR HRP20161333TT patent/HRP20161333T1/hr unknown
- 2016-10-13 SM SM201600370T patent/SMT201600370B/it unknown
- 2016-10-17 CY CY20161101037T patent/CY1118207T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2605794T3 (da) | Oligonukleotidchelatkomplekser | |
| JP6294308B2 (ja) | オリゴヌクレオチドキレート錯体方法 | |
| CA2873529C (en) | Oligonucleotide chelate complex-polypeptide compositions and methods |